ALK and neoplasm: SK-N-AS, which exhibits very low ALK surface expression, did not demonstrate complete and sustained tumor regressions but the transient anti-tumor activity suggests the presence of bystander cytotoxicity and potential to provide adjuvant therapeutic benefit in low ALK-expressing tumors.